European Immunization Week 2018- Statement of Guido Rasi, Executive Director, European Medicines Agency

Posted on: 26/04/2018 - 13:27

Vaccines matter for each of us: yearly, they prevent 2.7 million people from contracting measles, one million from getting whooping cough and two million babies from getting tetanus. They eradicated smallpox. They stopped polio, a dreadful disease affecting millions of children, in almost all... more

Field of Interest: European Union Medical News
Type: News Feed

Human medicines European public assessment report (EPAR): Datopotamab deruxtecan Daiichi Sankyo, datopotamab deruxtecan, Status: Application withdrawn

Submitted by Anonymous (not verified) on 11 November 2025 - 15:50

Human medicines European public assessment report (EPAR): Datopotamab deruxtecan Daiichi Sankyo, datopotamab deruxtecan, Status: Application withdrawn

Human medicines European public assessment report (EPAR): Slenyto, melatonin, Date of authorisation: 20/09/2018, Revision: 14, Status: Authorised

Submitted by Anonymous (not verified) on 11 November 2025 - 15:42

Human medicines European public assessment report (EPAR): Slenyto, melatonin, Date of authorisation: 20/09/2018, Revision: 14, Status: Authorised

Human medicines European public assessment report (EPAR): Uzpruvo, ustekinumab, Date of authorisation: 05/01/2024, Revision: 8, Status: Authorised

Submitted by Anonymous (not verified) on 11 November 2025 - 15:22

Human medicines European public assessment report (EPAR): Uzpruvo, ustekinumab, Date of authorisation: 05/01/2024, Revision: 8, Status: Authorised

Human medicines European public assessment report (EPAR): Kaftrio, ivacaftor,tezacaftor,elexacaftor, Date of authorisation: 21/08/2020, Revision: 31, Status: Authorised

Submitted by Anonymous (not verified) on 11 November 2025 - 14:25

Human medicines European public assessment report (EPAR): Kaftrio, ivacaftor,tezacaftor,elexacaftor, Date of authorisation: 21/08/2020, Revision: 31, Status: Authorised

Human medicines European public assessment report (EPAR): Norvir, ritonavir, Date of authorisation: 25/08/1996, Revision: 71, Status: Authorised

Submitted by Anonymous (not verified) on 11 November 2025 - 12:50

Human medicines European public assessment report (EPAR): Norvir, ritonavir, Date of authorisation: 25/08/1996, Revision: 71, Status: Authorised

Human medicines European public assessment report (EPAR): Bimervax, COVID-19 Vaccine (recombinant, adjuvanted), Date of authorisation: 30/03/2023, Revision: 12, Status: Authorised

Submitted by Anonymous (not verified) on 11 November 2025 - 12:15

Human medicines European public assessment report (EPAR): Bimervax, COVID-19 Vaccine (recombinant, adjuvanted), Date of authorisation: 30/03/2023, Revision: 12, Status: Authorised

Human medicines European public assessment report (EPAR): Roctavian, valoctocogene roxaparvovec, Date of authorisation: 24/08/2022, Revision: 9, Status: Authorised

Submitted by Anonymous (not verified) on 11 November 2025 - 12:00

Human medicines European public assessment report (EPAR): Roctavian, valoctocogene roxaparvovec, Date of authorisation: 24/08/2022, Revision: 9, Status: Authorised

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Latest Newsletters

More
randomness